New hope for Tough-to-Treat colorectal cancer?
NCT ID NCT05854498
First seen Apr 23, 2026 · Last updated Jun 05, 2026 · Updated 8 times
Summary
This study tests whether a new combination of three drugs (liposomal irinotecan, TAS102, and bevacizumab) can help people with advanced colorectal cancer that has stopped responding to standard treatments. The trial will enroll 50 adults whose cancer has spread or cannot be removed. The goal is to see if the combination can slow cancer growth or shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Wisconsin Carbone Cancer Center
RECRUITINGMadison, Wisconsin, 52792, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.